目的 探討芪藶強(qiáng)心聯(lián)合丹參酮Ⅱ_A磺酸鈉治療心肌梗死的臨床療效。方法 選取2016年6月—2017年6月在焦作煤業(yè)（集團(tuán)）有限責(zé)任公司中央醫(yī)院治療的心肌梗死患者88例，根據(jù)用藥差別分為對照組（44例）和治療組（44例）。對照組靜脈滴注丹參酮Ⅱ_A磺酸鈉注射液，80 mg加入生理鹽水250 mL，1次/d；治療組在對照組基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組均經(jīng)過4周治療。觀察兩組患者臨床療效，比較治療前后兩組患者心功能指標(biāo)、6 min步行距離（6 WMT）和血清學(xué)指標(biāo)。結(jié)果 治療后，對照組和治療組臨床總有效率分別為79.55%、95.45%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左心室舒張末期容積（LVEDV）、左心室收縮末期容積（LVESV）和左室舒張末期內(nèi)經(jīng)（LVEDD）均明顯降低，左心室射血分?jǐn)?shù)（LVEF）和6 WMT明顯增加，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組心功能指標(biāo)和6 WMT改善水平顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清組織型纖溶酶原激活物抑制物1（PAI-1）、心肌肌鈣蛋白I（cTnI）、N末端B型鈉尿肽原（NT-proBNP）、心型脂肪酸結(jié)合蛋白（H-FABP）、可溶性CD40配體（sCD40L）水平均顯著降低（P<0.05）；且治療組血清學(xué)指標(biāo)水平顯著低于對照組（P<0.05）。結(jié)論 芪藶強(qiáng)心聯(lián)合丹參酮Ⅱ_A磺酸鈉治療心肌梗死可有效改善患者心功能，改善血清細(xì)胞因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Qili Qiangxin Capsules combined with sulfotanshinone sodium in treatment of myocardial infarction. Methods Patients (88 cases) with myocardial infarction in Jiaozuo Coal Industry Group Central Hospital from June 2016 to June 2017 were divided into control (44 cases) and treatment (44 cases) groups based on different treatments. Patients in the control group were iv administered with Sulfotanshinone Sodium Injection, 80 mg added into normal saline 150 mL, once daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function, 6 WMT and serum cytokine levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.55% and 95.45%, respectively, and there were differences between two groups (P < 0.05). After treatment, the LVEDV, LVESV and LVEDD in two groups were significantly decreased, but LVEF and 6 WMT were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the cardiac function and 6 WMT in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the PAI-1, cTnI, NT-proBNP, H-FABP and sCD40L levels in two groups were obviously decreased (P < 0.05). And the serum cytokine levels in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qili Qiangxin Capsules combined with sulfotanshinone sodium in treatment of myocardial infarction can effectively improve cardiac function and serum cytokines level, which has a certain clinical application value.